menu search

ATRA / Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics' Third Quarter 2023 Financial Results Conference Call. Read More
Posted: Nov 4 2023, 11:45
Author Name: Seeking Alpha
Views: 022956

ATRA News  

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 4, 2023

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corpora more_horizontal

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 8, 2023

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares t more_horizontal

Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

By Business Wire
June 7, 2023

Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its n more_horizontal

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 8, 2023

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares t more_horizontal

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

By InvestorPlace
April 16, 2023

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. more_horizontal

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
February 8, 2023

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the more_horizontal

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
November 8, 2022

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the more_horizontal

After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)

By Zacks Investment Research
August 2, 2022

After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)

Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combine more_horizontal


Search within

Pages Search Results: